• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    SARS-CoV-2 R&D: Is It Over?

    Sustainability: A New Threat or Opportunity for CDMOs?

    Advanced Therapy Manufacturing

    Advanced Therapy Packaging Trends

    CEO Spotlight: Darren Head
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Mirum Pharmaceuticals Acquires San Diego-based Satiogen

    Catalyst Biosciences Sells Complement Portfolio to Vertex Pharmaceuticals

    Insmed Appoints Drayton Wise as Chief Commercial Officer

    Clinigen Expands U.S. Site Capacity

    Corealis CDMO Completes Deal with ArchiMed
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Risk Assessment for a Nitrosamine Contamination of Peptide APIs Manufactured by SPPS

    Clinigen Expands U.S. Site Capacity

    Corealis CDMO Completes Deal with ArchiMed

    Piramal Pharma Solutions Upgrades Oral Solid Dose Capabilities

    Lonza, IBF Partner on Drug Development, Manufacture for Portfolio Cos
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    Royalty Pharma and Jefferies Invest $111M in ApiJect

    Cryoport Acquires Cell&Co BioServices for €6.2M

    Challenges of Developing Large Volume Drug/Device Combination Products for Parenteral SC Delivery

    Yourway Adds Capacity for Controlled Ambient Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    How Can Automation Optimize Immunohistochemistry?

    Corealis CDMO Completes Deal with ArchiMed

    Lonza, IBF Partner on Drug Development, Manufacture for Portfolio Cos

    Aptamer Group and PinotBio Extend Collaboration Agreement

    Selecting a CMO Partner for Sterile Injectable Manufacturing
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    FDA Inspection Trends Update

    Phase-Appropriate cGMP Considerations for Cell and Gene Therapy

    Sustainability: A New Threat or Opportunity for CDMOs?

    In Pursuit of Sustainability: How the Biopharma Industry Can Contribute

    Conducting Clinical Trials During the Pandemic: What Did We Learn?
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Qosina

    Kyongbo Pharmaceutical

    CMC Pharmaceuticals

    Alcami
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Qosina

    Kyongbo Pharmaceutical

    CMC Pharmaceuticals

    Alcami
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Breaking News

    Altor BioScience and CMC Biologics Team Up

    CMC to manufacture and validate Altor’s IL-15 superagonist molecule, ALT-803, for use in Phase 3 trials

    Related CONTENT
    • Selexis SA Appoints Hoffmann-Hecht CBO
    • Reshaping the Pharmaceutical Supply Chain
    • Batavia Biosciences
    • Vetio Animal Health
    • Evotec Opens U.S. HQ in NJ
    04.18.17
    CMC ICOS Biologics and Altor BioScience Corporation have entered into a manufacturing agreement for the cGMP manufacturing of Altor’s ALT-803 molecule for use in Phase 3 clinical trials.

    ALT-803 is a novel IL-15 superagonist complex consisting of an IL-15 mutant (IL-15N72D) bound to an IL-15Rα/IgG1 Fc fusion protein. Preclinical studies have shown that ALT-803 simultaneously mobilizes both the innate and adaptive arms of the immune system to elicit rapid and durable responses against numerous cancers and virally infected cells. Due to its robust immunostimulatory capacity for NK and T cells, Altor is developing ALT-803 for oncology and infectious disease indications. The molecule is currently part of an extensive development program, including ongoing clinical trials for the treatment of patients for various solid and hematological malignancies, such as non-muscle invasive bladder cancer, relapsed or refractory indolent B cell non-Hodgkin lymphoma (iNHL) and non-small cell lung cancer.

    “We selected CMC Biologics as our manufacturing partner for ALT-803 because of their demonstrated technical expertise manufacturing complex cell culture processes, including fusion proteins,” said Hing Wong, chief executive officer, Altor. “The successful transfer and manufacture of ALT-803 is vital to meeting our timelines as we advance our molecule towards pivotal studies. Furthermore, we are also exploring new applications for ALT-803 based combination approaches with other immunotherapies to further boost the immune response in patients with cancer or infectious diseases.”

    Gustavo Mahler, president and chief executive officer, CMC Biologics,” said, “We are delighted that Altor has selected CMC Biologics as their contract manufacturing organization (CMO) for ALT-803. CMC has a great deal of experience manufacturing Phase 3 candidates, and we are equipped to support potential scale-up needs utilizing our Bioreactor 3PACK and 6PACK facilities, should the demand for ALT-803 escalate beyond the current projected batch quantities. We look forward to working with the Altor team to successfully move this molecule to the next phase.” 
    Related Searches
    • biologics
    • cGMP
    • CMC
    • Development
    Suggested For You
    Selexis SA Appoints Hoffmann-Hecht CBO Selexis SA Appoints Hoffmann-Hecht CBO
    Reshaping the Pharmaceutical Supply Chain Reshaping the Pharmaceutical Supply Chain
    Batavia Biosciences Batavia Biosciences
    Vetio Animal Health Vetio Animal Health
    Evotec Opens U.S. HQ in NJ Evotec Opens U.S. HQ in NJ
    INC Research, inVentiv Health to Merge INC Research, inVentiv Health to Merge
    Leveraging Next-Gen FSP Models to Better Manage Post-approval Regulatory Workloads Leveraging Next-Gen FSP Models to Better Manage Post-approval Regulatory Workloads
    Astellas Names President of Astellas US Technologies Astellas Names President of Astellas US Technologies
    CMC Expands to Offer cGMP Processing CMC Expands to Offer cGMP Processing
    Permira Funds Acquires LSNE Permira Funds Acquires LSNE
    CMO Bushu and Takeda Form Partnership CMO Bushu and Takeda Form Partnership
    Q Laboratories Names Chief Executive Q Laboratories Names Chief Executive
    Navigating the Shifting Landscape of Contract API Manufacturing Navigating the Shifting Landscape of Contract API Manufacturing
    Pharmaron Acquires Xceleron Pharmaron Acquires Xceleron
    Eurofins Acquires Villapharma in Spain Eurofins Acquires Villapharma in Spain

    Related Content

    • Promotions & Moves
      Selexis SA Appoints Hoffmann-Hecht CBO

      Selexis SA Appoints Hoffmann-Hecht CBO

      Dr. Hoffmann-Hecht will serve on the executive leadership team and will report to Selexis CEO Dirk Lange.
      Kristin Brooks 06.02.21

    • Cold Chain Management | Logistics | Packaging & Tracking | Supply Chain
      Reshaping the Pharmaceutical Supply Chain

      Reshaping the Pharmaceutical Supply Chain

      The pandemic and COVID-19 vaccines bring navigating the cold-chain and preserving precious biologics to the forefront.
      Kristin Brooks, Managing Editor 03.01.21

    • Batavia Biosciences

      ...
      Claire Otjes, Marketing Manager 11.20.20


    • Vetio Animal Health

      Vetio Animal Health

      ...
      John Kane, CEO 10.24.19

    • Breaking News | Drug Development | Drug Discovery | Facilities | Industry News
      Evotec Opens U.S. HQ in NJ

      Evotec Opens U.S. HQ in NJ

      Also unveils 20,000 square-foot facility expansion
      05.26.17

      Trending
      • How Can Automation Optimize Immunohistochemistry? | Contract Pharma
      • Catalyst Biosciences Sells Complement Portfolio To Vertex Pharmaceuticals | Contract Pharma
      • Corealis CDMO Completes Deal With ArchiMed | Contract Pharma
      • Mirum Pharmaceuticals Acquires San Diego-based Satiogen | Contract Pharma
      • Lonza Invests In Additional Inhalation Capabilities In Tampa | Contract Pharma
      Breaking News
      • CureVac, myNEO Partner on Antigen Targets for mRNA-Cancer Vax Development
      • Mirum Pharmaceuticals Acquires San Diego-based Satiogen
      • Catalyst Biosciences Sells Complement Portfolio to Vertex Pharmaceuticals
      • Insmed Appoints Drayton Wise as Chief Commercial Officer
      • Clinigen Expands U.S. Site Capacity
      View Breaking News >
      CURRENT ISSUE

      May 2022

      • Sustainability and the Biopharma Industry
      • Contract Manufacturing During COVID
      • Orphan Drugs in the United States
      • CEO Spotlight: Peter DeYoung
      • CEO Spotlight: Darren Head
      • Advanced Therapy Packaging Trends
      • Advanced Therapy Manufacturing
      • Sustainability: A New Threat or Opportunity for CDMOs?
      • SARS-CoV-2 R&D

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Thorne Relaunches Gut Health Test with Microbiome Wipe
      Alkemist Labs Announces Alkemist Assured Seal and Next Generation Transparency Reports
      GC Rieber Foundations Expand Philanthropic Efforts
      Coatings World

      Latest Breaking News From Coatings World

      PPG Hosts The Future of Coatings' Technology Innovation Day in Amsterdam
      Azelis Expands Presence in India with Acquisition of Chemo India and Unipharm Laboratories
      Teknos Publishes Sustainability Report
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      Vector Remote Care Rolls Out New Cardiac Care Software Platform
      FDA OKs Apyx Medical's Renuvion for Dermal Resurfacing
      Blue Spark Technologies Raises $40 Million
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Mirum Pharmaceuticals Acquires San Diego-based Satiogen
      Catalyst Biosciences Sells Complement Portfolio to Vertex Pharmaceuticals
      Insmed Appoints Drayton Wise as Chief Commercial Officer
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      La Roche-Posay Launches Matte Moisturizer for Oily Skin
      3 Amorepacific Employees Stole $2.3 Million
      L'Oreal CEO Nicolas Hieronimus On Sustainability Initiatives
      Happi

      Latest Breaking News From Happi

      Thayers Natural Remedies Celebrates 175 Years with Social Campaign
      Former Model Shirley Powell’s Indie Beauty Brand LaJeanell Comprises Gender Inclusive Skincare and Makeup
      L’Oréal's New UVMune 400 Sun Filtering Technology Protects Skin From Ultra-Long UVA Rays
      Ink World

      Latest Breaking News From Ink World

      CEMATEX Introduces Online Business Platform to Connect Global Textile Community
      PICO Chemical Celebrates 46 Years
      Epson Introduces Two New SurePress Digital Label Presses
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      AWA to host 22nd Global Release Liner Industry Conference & Exhibition
      Domino assists Grace Label with supply chain disruptions
      Rotocon wins AI Business Excellence Award
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Rael Raises $35M in Series B Funding
      Schobertechnologies Offers Rotary Web-fed Converting Solutions
      Thorne Relaunches Gut Health Test with Microbiome Wipe
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Emovi, Geneva Foundation Providing Knee Treatment Tech to U.S. Army
      Study Confirms Knee Shapes are Highly Individualized
      Stryker Launches EasyFuse Dynamic Compression for Foot & Ankle
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      ARPA-E Funding Drives Innovation, Industry Partnerships at NREL
      InnovationLab Acquires Flexible Printed Battery Technology from Evonik
      Canatu Receives IATF 16949:2016 Certification

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login